EQL PHARMA AB (F:7JK) — Stock Price

€1.82 EUR
▲ 0.44% today

EQL PHARMA AB (F:7JK) is currently trading at €1.82 EUR, up 0.44% today. Over the past 52 weeks, shares have ranged between €1.76 and €7.89. This page tracks EQL PHARMA AB's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 7JK market cap.

EQL PHARMA AB (7JK) Stock Price Chart — Daily History & Trading Volume

The chart below tracks EQL PHARMA AB's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.

EQL PHARMA AB Income Statement — Revenue, Profit & Earnings by Year

EQL PHARMA AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 2025202420232022
Total Revenue €373.52 Million €264.17 Million €259.91 Million €409.75 Million
Cost of Revenue €217.56 Million €149.12 Million €144.06 Million €314.02 Million
Gross Profit €155.95 Million €115.05 Million €115.85 Million €95.73 Million
Research & Development €11.26 Million €12.09 Million €15.14 Million €9.13 Million
SG&A €78.46 Million €70.80 Million €59.79 Million €48.16 Million
Total Operating Expenses €307.17 Million €231.93 Million €218.81 Million €371.19 Million
Operating Income €66.35 Million €32.24 Million €41.11 Million €38.56 Million
EBITDA
EBIT
Interest Expense €12.34 Million €5.73 Million €2.37 Million €2.87 Million
Income Before Tax €54.35 Million €28.60 Million €38.97 Million €35.97 Million
Income Tax Expense
Net Income €43.12 Million €22.70 Million €30.92 Million €31.55 Million

EQL PHARMA AB Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes EQL PHARMA AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 2025202420232022
Total Assets €808.82 Million €373.76 Million €285.70 Million €237.89 Million
Total Current Assets €400.25 Million €197.77 Million €167.23 Million €123.45 Million
Cash & Equivalents
Short-term Investments
Net Receivables €125.68 Million €58.34 Million €51.70 Million €34.10 Million
Inventory €179.03 Million €105.63 Million €65.37 Million €41.67 Million
Property, Plant & Equipment
Goodwill
Total Liabilities €587.79 Million €196.03 Million €130.94 Million €114.26 Million
Total Current Liabilities €221.02 Million €162.05 Million €117.19 Million €98.76 Million
Long-term Debt €338.39 Million €15.45 Million €0.00 €7.20 Million
Net Debt €367.51 Million €97.20 Million €19.27 Million €30.72 Million
Total Stockholder Equity €221.03 Million €177.73 Million €154.75 Million €123.63 Million
Retained Earnings €152.08 Million €108.97 Million €86.26 Million €55.33 Million

EQL PHARMA AB Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how EQL PHARMA AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 2025202420232022
Operating Cash Flow €-24.65 Million €-11.44 Million €27.62 Million €41.83 Million
Capital Expenditures €245.84 Million €66.26 Million €20.51 Million €22.09 Million
Free Cash Flow €-270.49 Million €-77.70 Million €7.11 Million €19.74 Million
Investing Cash Flow
Financing Cash Flow
Dividends Paid
Stock-Based Compensation
Depreciation €12.52 Million €8.75 Million €14.19 Million €10.27 Million
Change in Cash €61.93 Million €-23.96 Million €3.23 Million €14.62 Million

EQL PHARMA AB Earnings History — EPS Actual vs. Analyst Estimates

Track EQL PHARMA AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 08, 2025